Treatment of patients with chronic cerebral ischemia: experience of using the combined neuroprotective drug Picamilon Ginkgo

Zaharov V.V.; Borodulina I.V.; Vakhnina N.V.

doi:https://doi.org/10.17116/jnevro202212209195

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

SPIN RSCI: 6404-1030
Scopus AuthorID: 7402991374
ORCID: 0000-0002-8447-3264

Borodulina I.V.

Russian Medical Academy for Continuous Professional Education

Vakhnina N.V.

Sechenov First Moscow State Medical University

ORCID: 0000-0002-0834-4030

Treatment of patients with chronic cerebral ischemia: experience of using the combined neuroprotective drug Picamilon Ginkgo

Authors:

Zaharov V.V., Borodulina I.V., Vakhnina N.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(9): 95‑103

DOI: 10.17116/jnevro202212209195

Read: 14346 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Zaharov VV, Borodulina IV, Vakhnina NV. Treatment of patients with chronic cerebral ischemia: experience of using the combined neuroprotective drug Picamilon Ginkgo. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(9):95‑103. (In Russ.)
https://doi.org/10.17116/jnevro202212209195

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To compare the clinical efficacy and safety of Picamilon Ginkgo and ginkgo biloba in patients with cognitive impairment in vascular diseases of the brain (chronic cerebral ischemia).

MATERIAL AND METHODS

An open multicenter randomized comparative study involved 278 patients over 45 years of age with a diagnosis of chronic cerebral ischemia and cognitive impairment. 139 of them received Picamilon Ginkgo and 139 received monotherapy with ginkgo biloba extract for 90 days. Dynamics were compared on the MoCA, MMSE, Hamilton scale for assessing depression and the quality of life of EQ-5D, and the subjective effectiveness of therapy by patients and doctors was evaluated.

RESULTS

Combination therapy resulted in significantly greater regression of cognitive impairment compared to monotherapy. At the end of the study, the differences between the groups were significant both on the MMSE scale (p=0.007) and on the MoCA scale (p=00003). At the same time, significant differences between the groups in the magnitude of cognitive improvement on the MoCA scale were noted already from the 30th day of treatment. Combination therapy also contributed to a more significant improvement in the patient’s quality of life: dynamics on the EQ-5D scale significantly (p<0.05) differed in the groups, also starting from the 30th day of therapy. There were no significant differences in the dynamics of the Hamilton scale for assessing depression between the compared groups. Both Picamilon Ginkgo and monotherapy with ginkgo biloba extract were safe and were not accompanied by significant adverse events.

CONCLUSION

The combination of standardized ginkgo biloba extract with Picamilon has an advantage over monotherapy with ginkgo biloba extract in patients with chronic cerebral ischemia, as it contributes to a more significant regression of cognitive impairment and improvement of quality of life.

Keywords:

chronic cerebral ischemia

cognitive impairment

vascular cognitive impairment

moderate cognitive impairment

cerebrovascular diseases

neurometabolic therapy

Picamilon Ginkgo

gingko biloba

Authors:

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

SPIN RSCI: 6404-1030
Scopus AuthorID: 7402991374
ORCID: 0000-0002-8447-3264

Borodulina I.V.

Russian Medical Academy for Continuous Professional Education

Vakhnina N.V.

Sechenov First Moscow State Medical University

ORCID: 0000-0002-0834-4030

Received:

25.07.2022

Accepted:

03.08.2022

Close metadata

References:

Wardlaw JM, Smith EE, Biessels GJ, et al. STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822-838. https://doi.org/10.1016/S1474-4422(13)70124-8
Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9:689-701. https://doi.org/10.1016/S1474-4422(10)70104-6
Cannistraro RC, Badi M, Eidelman BH, et al. CNS small vessel disease. A clinical review. Neurology. 2019;92:1146-1156. https://doi.org/10.1212/WNL.0000000000007654
Caplan LR. Lacunar infarction and small vessel disease: pathology and pathophysiology. Stroke. 2015;17(1):2-6. https://doi.org/10.5853/jos.2015.17.1.2
Greenberg SM, Vernooij MW, Cordonnier C, et al. Microbleed Study Group. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 2009;8:165-174. https://doi.org/10.1016/S1474-4422(09)70013-4
Yakhno NN, Levin OS, Damulin IV. Comparison of clinical and MRI data in dyscirculatory encephalopathy. Post 2: Cognitive impairment. Nevrologicheskij zhurnal. 2001;6(3):10-19. (In Russ.).
Filley CM, Fields RD. White matter and cognition: making the connection. J Neurophysiol. 2016;116(5):2093-2104. https://doi.org/10.1152/jn.00221.2016
Lei C, Deng Q, Li H, Zhong L. Association Between Silent Brain Infarcts and Cognitive Function: A Systematic Review and Meta-Analysis. J Stroke Cerebrovasc Diss. 2019;28(9):2376-2387. https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.03.036
Martinez-Ramirez S, Greenberg SM, Viswanathan A. Cerebral microbleeds: overview and implications in cognitive impairment. Alzheimer’s Res & Ther. 2014;6(3):33. https://doi.org/10.1186/alzrt263
Moulin S, Cordonnier C. Role of Cerebral Microbleeds for Intracerebral Haemorrhage and Dementia. Curr Neurol Neurosci Rep. 2019;19(8):51-55. https://doi.org/10.1007/s11910-019-0969-0
Kulesh AA, Emelin AYu, Bogolepova AN, et al. Clinical manifestations and diagnostic issues of chronic cerebrovascular disease (chronic cerebral ischemia) at an early (pre-dement) stage. Nevrologiya, nejropsihiatriya, psihosomatika. 2021;13(1):4-12. (In Russ.). https://doi.org/10.14412/2074-2711-2021-1-4-12
Bryzhakhina VG, Damulin IV, Yakhno NN. Walking and balance disorders in dyscirculatory encephalopathy. Message 1. Nevrologicheskij zhurnal. 2004;9(2):11-16. (In Russ.).
Yakhno NN, Levin OS, Damulin IV. Comparison of clinical and MRI data in dyscirculatory encephalopathy. Message 1: Motor disorders. Nevrologicheskij zhurnal. 2001;6(2):10-16. (In Russ.).
Bogolepova AN. Vascular depression and cognitive dysfunction. Nevrologiya, nejropsihiatriya, psihosomatika. 2019;11(3):26-31. (In Russ.). https://doi.org/10.14412/2074-2711-2019-3S-26-31
Gorelick PB, Scuteri A, Black SE, et al. American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42(9):2672-2713. https://doi.org/10.1161/STR.0b013e3182299496
Haag MD, Hofman A, Koudstaal PJ, et al. Duration of antihypertensive drug use and risk of dementia: a prospective cohort study. Neurology. 2009;72(20):1727-1234. https://doi.org/10.1212/01.wnl.0000345062.86148.3f
Peila R, White LR, Masaki K, et al. Reducing the risk of dementia: efficacy of long term treatment of hypertension. Stroke. 2006;37:1165-1170. https://doi.org/10.1161/01.STR.0000217653.01615.93
Khachaturian AS, Zandi PP, Lyketsos CG, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arc Neurol. 2006;63(5):686-692. https://doi.org/10.1001/archneur.63.5.noc60013
Qiu C, von Strauss E, Fastbom J, et al. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arc Neurol. 2003;60(2):223-228. https://doi.org/10.1001/archneur.60.2.223
Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352(9137):1347-1351. https://doi.org/10.1016/s0140-6736(98)03086-4
Tzourio C, Anderson C, Chapman N, et al. PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arc Int Med. 2003;163(9):1069-1075. https://doi.org/10.1001/archinte.163.9.1069
Diener HC, Sacco RL, Yusuf S, et al. Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7(10):875-884. https://doi.org/10.1016/S1474-4422(08)70198-4
Lithell H, Hansson L, Skoog I, et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertension. 2003;21(5):875-886. https://doi.org/10.1097/00004872-200305000-00011
Peters R, Beckett N, Forette F, et al. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7(8):683-689. https://doi.org/10.1016/S1474-4422(08)70143-1
Trompet S, van Vliet P, de Craen AJ, et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol. 2010;257(1):85-90. https://doi.org/10.1007/s00415-009-5271-7
Price JF, Stewart MC, Deary IJ, et al. Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial. BMJ. 2008;337:a1198. https://doi.org/10.1136/bmj.a1198
Azhikova AK. Ginkgo biloba (ginkgo biloba L.): prospects for use in pharmacy. Prikaspijskij vestnik mediciny i farmacii. 2020;1(1):6-13. (In Russ.). https://doi.org/10.17021/2020.1.1.6.13
Burchinsky SG. Ginkgo biloba preparations: on the path of discoveries in clinical neuropharmacology. Mezhdunarodnyj nevrologicheskij zhurnal. 2016;4(82):83-87. (In Russ.). https://doi.org/10.22141/2224-0713.4.90.2017.107261
Yakhno NN, Damulin IV, Zakharov VV, et al. The use of tanakan in the initial stages of cerebral vascular insufficiency: results of an open multicenter study. Nevrologicheskij zhurnal. 1998;3(6):18-22. (In Russ.).
Yakhno NN, Zakharov VV, Lokshina AB, et al. Tanakan (Egb 761) in the therapy of moderate cognitive impairment (multicenter study). ZHurnal nevrologii i psihiatrii im. S.S. Korsakova. 2006;106(12):41-46. (In Russ.).
Savaskan E, Mueller H, Hoerr R, von Gunten A, Gauthier S. Treatment effects of Ginkgo biloba extract EGb 761 on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials. International Psychogeriatrics. 2018;30(3):285-293. https://doi.org/10.1017/S1041610217001892
Vellas B, Coley N, Ousset PJ, et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012;11(10):851-859. https://doi.org/10.1016/S1474-4422(12)70206-5
Dodge HH, Zitzelberger T, Oken BS, et al. A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. Neurology. 2008;6(2):1809-1817. https://doi.org/10.1212/01.wnl.0000303814.13509.db
Mitrokhin KV, Baranishin AA. Classification and brief description of medicinal preparations — analogues of derivatives of gamma-aminobutyric acid and toxic substances affecting the gabaergic bond. Anesteziologiya i reanimatologiya. 2018;6:22-30. (In Russ.). https://doi.org/10.17116/anaesthesiology201806122
Perfilova VN, Borodkina LE. Participation of the gamma-aminobutyric acid-ergic system in the regulation of cerebral circulation. Vestnik Rossijskoj voenno-medicinskoj akademii. 2014;1(45):203-211. (In Russ.).
Mirzoyan RS, Ganshina TS, Kim GA, et al. Translational potential of experimental pharmacology of cerebrovascular disorders. Annaly klinicheskoj i eksperimental’noj nevrologii. 2019;13(3):34-40. (In Russ.). https://doi.org/10.25692/ACEN.2019.3.5
Latysheva VYa, Galinovskaya NV, Shaporova OV, et al. Treatment of patients with dyscirculatory encephalopathy. Recept. 2008;3(59):69-75. (In Russ.).
Likhodeeva VA, Spasov AA, Isupov IB, Mandrikov VB. The effect of picamilon on the parameters of cerebral blood flow of disadapted swimmers with different types of systemic hemodynamics. Vestnik novyh medicinskih tekhnologij. 2011;18(1):150-153. (In Russ.).
Sakharov VYu, Skripnik YuV. The use of picamilon in restorative treatment in post-stroke patients with emotional and cognitive impairments. Nevrologiya. 2021;12:309-310. (In Russ.).
Sidorenko EV. Methods of mathematical processing in psychology. SPb.: OOO «Rech’», 2003. (In Russ.).